Coherus Oncology (CHRS) Price to Earnings (2014 - 2026)

Coherus Oncology has disclosed Price to Earnings across 13 years of filings, most recently posting 10.48 for Q2 2026.

• In Q2 2026, Price to Earnings fell 3778.88% year-over-year to 10.48; the TTM figure through Jun 2026 stood at 1.64 (down 446.75% YoY), while the FY2025 annual figure was 0.83, down 61.49% from the prior year.
• Price to Earnings came in at 10.48 for Q2 2026 at Coherus Oncology, down from 6.8 in the prior quarter.
• In the past five years, Price to Earnings ranged from a high of 2.64 in Q1 2024 to a low of 15.42 in Q2 2024.
• Average Price to Earnings over 5 years is 7.12, with a median of 7.95 recorded in 2022.
• Year-over-year, Price to Earnings surged 136.27% in 2024 and plunged 3778.88% in 2026.
• Over 5 years, Price to Earnings stood at 10.61 in 2022, then surged by 55.78% to 4.69 in 2023, then soared by 32.92% to 3.15 in 2024, then plunged by 45.22% to 4.57 in 2025, then plunged by 129.35% to 10.48 in 2026.
• Per Business Quant data, the three most recent Price to Earnings figures were 10.48 in Q2 2026, 6.8 in Q1 2026, and 4.57 in Q4 2025.